PL Lodz Watala C: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
|country=Poland | |country=Poland | ||
|MiPNetLab=Watala C, Labieniec M, Siewiera K | |MiPNetLab=Watala C, Labieniec M, Siewiera K | ||
|info=[http://www.oroboros.at/?IOC55-56 IOC55-56 | |info=[[IOC61]], [http://www.oroboros.at/?IOC55-56 IOC55-56] | ||
}} | }} | ||
*Mitochondrial respiratory capacity | * Mitochondrial respiratory capacity under normal and pathophysiological conditions (diabetes mellitus, atherothrombosis, brain-blood barrier disruption, cancerogenesis) | ||
*Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity | * Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity | ||
* | * Targeting of biochemical and molecular burden of diabetes | ||
Revision as of 11:45, 4 June 2012
- Mitochondrial respiratory capacity under normal and pathophysiological conditions (diabetes mellitus, atherothrombosis, brain-blood barrier disruption, cancerogenesis)
- Pharmacological modulation of mitochondrial function by selected pharmaceuticals of anti-diabetic activity
- Targeting of biochemical and molecular burden of diabetes
